Gastrointestinal symptoms in cancer patients with advanced disease
- 1 March 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Supportive & Palliative Care
- Vol. 6 (1), 69-76
- https://doi.org/10.1097/spc.0b013e32834f689d
Abstract
This review summarizes recent developments in the management of gastrointestinal symptoms experienced by cancer patients and provides a framework for education, assessment and monitoring, and treatment. Although many viable treatment options exist, gastrointestinal symptoms - particularly nausea and vomiting, constipation, and diarrhea - continue to challenge both patients and clinicians. Current clinical guidelines now recommend that patients treated with moderate emetic risk chemotherapy regimens be preferentially treated with the 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, palonosetron, in combination with dexamethasone. A large randomized trial has also recently validated that single-dose fosaprepitant is equivalent to the standard 3-day, aprepitant regimen. New medications, such as skin patch delivery of granisetron for nausea or methylnaltrexone for constipation, show promise in both the management of symptoms and as preventive agents. The integration of complementary and alternative therapies, such as relaxation techniques, ginger, and electroacupuncture may also assist with symptom relief. Accurate assessment is essential, but often problematic, especially as the patient's experience of gastrointestinal distress is often disproportionate with objective measures. New methodologies that harness technology to collect patient-reported outcomes may improve the accuracy of assessment, provide a better picture of the patient's experience of gastrointestinal symptoms, and deliver a means to simultaneously monitor symptoms, educate patients, and collect longitudinal data. Palliative management of gastrointestinal symptoms in advanced cancer patients requires a multipronged approach that entails effective assessment, judicious use of latest evidence-based approaches, and monitoring that incorporates both clinical measures and patient-reported outcomes. When combined with refinements in the overall clinical approach to symptom management, standardized instruments that streamline data collection and enable data warehousing will support better symptom management.Keywords
This publication has 52 references indexed in Scilit:
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Update and new trends in antiemetic therapy: the continuing need for novel therapiesAnnals of Oncology, 2010
- Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US populationSupportive Care in Cancer, 2010
- Evidence-Based Recommendations for Cancer Nausea and VomitingJournal of Clinical Oncology, 2008
- Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 2008
- Chemotherapy-Induced Nausea and VomitingThe Cancer Journal, 2008
- Letter to the editor: Use Intractable nausea and vomiting successfully related with granisetron 5-hydroxtrytamine type 3 receptor antagonists in Palliative MedicinePalliative Medicine, 2007
- Symptom Prevalence in Patients with Incurable Cancer: A Systematic ReviewJournal of Pain and Symptom Management, 2007
- An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancerSupportive Care in Cancer, 2005
- Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.BMJ, 1979